J Korean Med Assoc.  2006 Jan;49(1):48-52. 10.5124/jkma.2006.49.1.48.

Management of Late-onset Hypogonadism

• Seo JT

• KMID: 2184635
• DOI: http://doi.org/10.5124/jkma.2006.49.1.48

Abstract

There has been a great deal of recent interests in the topic of low testosterone in elderly men, a condition referred to as andropause, ADAM (androgen decline of aging male), or PADAM (partial androgen deficiency of the aging male), or LOH (late onset hypogonadism). Age-related decreases in androgen levels occur gradually and vary considerably among individuals. A low level of testosterone has been implicated as a cause of changes in sexual, physical and behavioral capacity in aging men. Although several observational and interventional studies have demonstrated that androgens have important beneficial functions in the body composition, muscle mass and strength, fat distribution, erythropoiesis, cognition, mood and bone density, and play a key role in male sexual function, a considerable controversy exists regarding the indications of testosterone supplementation in aging male.The objective of this article is to discuss what is known and not known regarding the benefits and risks of testosterone-replacement therapy and the monitoring of men receiving testosterone treatment.

Keyword

Hypogonadism; Testosterone; Aging

MeSH Terms

Aged
Aging
Androgens
Andropause
Body Composition
Bone Density
Cognition
Erythropoiesis
Humans
Hypogonadism*
Male
Risk Assessment
Testosterone
Androgens
Testosterone

Reference

1. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. Eur Urol. 2005. 48:1–4.

2. Karlsson MK, Hasserius R, Obrant KJ. Individuals who sustain nonosteoporotic fractures continue to also sustain fragility fractures. Calcif Tissue Int. 1993. 53:229–231.

3. Orwoll ES, Bevan L, Phipps KR. Determinants of bone mineral density in older men. Osteoporos Int. 2000. 11:815–821.

4. Orwoll ES. Osteoporosis in men. Primer on the metabolic bone diseases and disorders of mineral metabolism. 2003. 5th ed. American society for Bone and Mineral Research;360–364.

5. Orwoll ES, Klein RF. Marcus R, Feldman D, Kelsey J, editors. Osteoporosis in men: epidemiology, pathophysiology, and clinical characterization. Osteoporosis. 2001. 2nd ed. San Diego: Academic Press;103–149.

6. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Lombardi A, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000. 343:604–610.

7. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004. 172:658–663.

8. Holmang S, Marin P, Linstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle aged men. Prostate. 1993. 23:99–106.

9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001. 86:724–731.

10. Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD, Sweetnam PM, Riad-Fahmy D, et al. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol. 1987. 126:647–657.

11. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003. 24:299–311.

12. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996. 276:1904–1906.